Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · IEX Real-Time Price · USD

1.090

+0.010 (0.93%)

At close: Apr 26, 2024, 4:00 PM

1.070

-0.020 (-1.83%)

After-hours: Apr 26, 2024, 4:14 PM EDT

Oncolytics Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2000
Selling, General & Admin	16.08	11.49	13.32	12.51	9.56	7.24	6.21	5.52	5.32	5	Upgrade
Research & Development	17.71	15.43	12.92	12.95	10.82	10.03	9.39	9.77	8.6	13.82	Upgrade
Operating Expenses	33.79	26.92	26.24	25.46	20.38	17.27	15.61	15.29	13.92	18.82	Upgrade
Operating Income	-33.79	-26.92	-26.24	-25.46	-20.38	-17.27	-15.61	-15.29	-13.92	-18.82	Upgrade
Interest Expense / Income	0	0	0	0	0	0	0	-0.16	-0.2	-0.21	Upgrade
Other Expense / Income	-6.14	-2.17	0.02	-2.95	12.75	-0.78	-0.13	-	-	-	Upgrade
Pretax Income	-27.66	-24.75	-26.26	-22.51	-33.12	-16.49	-15.48	-15.13	-13.72	-18.61	Upgrade
Income Tax	0.1	0.08	0.05	0	0	0.55	0.14	0.01	0	0.01	Upgrade
Net Income	-27.75	-24.84	-26.3	-22.51	-33.12	-17.04	-15.62	-15.14	-13.72	-18.62	Upgrade
Shares Outstanding (Basic)	68	58	54	40	22	16	14	13	12	9	Upgrade
Shares Outstanding (Diluted)	68	58	54	40	22	16	14	13	12	9	Upgrade
Shares Change	16.53%	8.44%	32.66%	82.22%	38.22%	14.92%	10.44%	6.45%	28.16%	5.19%	Upgrade
EPS (Basic)	-0.41	-0.43	-0.49	-0.56	-1.50	-1.06	-1.12	-1.20	-1.14	-2.00	Upgrade
EPS (Diluted)	-0.41	-0.43	-0.49	-0.56	-1.50	-1.06	-1.12	-1.20	-1.14	-2.00	Upgrade
Free Cash Flow	-28.46	-23.41	-22.72	-22.1	-19.92	-12.03	-15	-12.5	-15.14	-19.83	Upgrade
Free Cash Flow Per Share	-0.42	-0.40	-0.42	-0.55	-0.90	-0.75	-1.08	-0.99	-1.28	-2.14	Upgrade
EBITDA	-27.25	-24.36	-25.8	-22.06	-32.64	-16.39	-15.38	-15.13	-13.74	-18.66	Upgrade
Depreciation & Amortization	0.4	0.39	0.45	0.45	0.49	0.1	0.09	0.16	0.18	0.16	Upgrade
EBIT	-27.66	-24.75	-26.26	-22.51	-33.12	-16.49	-15.48	-15.29	-13.92	-18.82	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).